Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quanta Brings Oxford Uni Money Man On Board

This article was originally published in Clinica

Executive Summary

Advanced hemodialysis systems firm Quanta Fluid Solutions Ltd has appointed Giles Kerr non-executive director. Kerr is currently Chief Financial Officer at Oxford University and non-executive director at the university’s technology transfer arm, ISIS Innovation. He also serves on the board of specialist healthcare company BTG plc, where he is the firm’s Chairman of the Audit Committee and Senior Independent Director. Privately-held Quanta is currently commercializing its CE-marked SC+ portable, compact hemodialysis system; after raising £27m in a series B round in November last year, CEO John Milad had told Clinica that the next fundraising would likely be an IPO, and indicated at that time it could happen “12-18 months” from then.

Advertisement

Related Content

Holding Out For Home Hemodialysis: Still-Modest Market Promises Bigger Growth

Topics

Advertisement
UsernamePublicRestriction

Register

MT102879

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel